Evidence map›Paper›PMID 24637461›Full record

ArticlePloS one2014

The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior.

Denise K Reaves, Katerina D Fagan-Solis, Karen Dunphy, Shannon D Oliver, David W Scott, Jodie M Fleming

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. LSR Promotes Cell Proliferation and Invasion in Lung Cancer.Computational and mathematical methods in medicine · 2021
    Article
  9. Review
  10. Leptin Downregulates Angulin-1 in Active Crohn's Disease via STAT3.International journal of molecular sciences · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.Journal of immunology (Baltimore, Md. : 1950) · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Denise K ReavesDepartment of Biology, North Carolina Central University, Durham, North Carolina, United States of America.
Katerina D Fagan-SolisDepartment of Biology, North Carolina Central University, Durham, North Carolina, United States of America.
Karen DunphyDepartment of Veterinary and Animal Sciences, University of Massachusetts, Amherst, Massachusetts, United States of America.
Shannon D OliverDepartment of Biology, North Carolina Central University, Durham, North Carolina, United States of America.
David W ScottDepartment of Cell Physiology and Cell Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Jodie M FlemingDepartment of Biology, North Carolina Central University, Durham, North Carolina, United States of America.
North Carolina Central University · USUniversity of Massachusetts Amherst · USUniversity of North Carolina at Chapel Hill · US

Funding

Integrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7M
Targeting the MEKK2-ERK5 Signaling Node in Triple Negative Breast CancerU54CA156735 · NCI · NORTH CAROLINA CENTRAL UNIVERSITY · PI RICHARDSON, MICHELER RICARDO · 2010 to 2021
$13.0M
Development of a novel targeted-therapy for treatment of basal-like breast cancerSC2CA176585 · NCI · NORTH CAROLINA CENTRAL UNIVERSITY · PI FLEMING, JODIE MICHELLE · 2012 to 2014
$374k
HGF signaling in African-American and Basal-like Breast CancerR21CA175783 · NCI · NORTH CAROLINA CENTRAL UNIVERSITY · PI FLEMING, JODIE MICHELLE, TROESTER, MELISSA A. · 2013 to 2014
$348k
NCI NIH HHS 5SC2CA176585-02NCI NIH HHS R21 CA175783NCI NIH HHS SC2 CA176585NCI NIH HHS T32 CA009156NCI NIH HHS U54 CA156735NCI NIH HHS U54 CA156735-03
6 · The paper itself

Abstract

The claudin-low molecular subtype of breast cancer is of particular interest for clinically the majority of these tumors are poor prognosis, triple negative, invasive ductal carcinomas. Claudin-low tumors are characterized by cancer stem cell-like features and low expression of cell junction and adhesion proteins. Herein, we sought to define the role of lipolysis stimulated lipoprotein receptor (LSR) in breast cancer and cancer cell behavior as LSR was recently correlated with tumor-initiating features. We show that LSR was expressed in epithelium, endothelium, and stromal cells within the healthy breast tissue, as well as in tumor epithelium. In primary breast tumor bioposies, LSR expression was significantly correlated with invasive ductal carcinomas compared to invasive lobular carcinomas, as well as ERα positive tumors and breast cancer cell lines. LSR levels were significantly reduced in claudin-low breast cancer cell lines and functional studies illustrated that re-introduction of LSR into a claudin-low cell line suppressed the EMT phenotype and reduced individual cell migration. However, our data suggest that LSR may promote collective cell migration. Re-introduction of LSR in claudin-low breast cancer cell lines reestablished tight junction protein expression and correlated with transepithelial electrical resistance, thereby reverting claudin-low lines to other intrinsic molecular subtypes. Moreover, overexpression of LSR altered gene expression of pathways involved in transformation and tumorigenesis as well as enhanced proliferation and survival in anchorage independent conditions, highlighting that reestablishment of LSR signaling promotes aggressive/tumor initiating cell behaviors. Collectively, these data highlight a direct role for LSR in driving aggressive breast cancer behavior.

Indexed as

BiopsyBreast NeoplasmsCell Line, TumorCell MovementCell SurvivalClaudinsFemaleGene ExpressionHumansImmunohistochemistryLipolysisReceptors, LipoproteinRisk FactorsTight JunctionsClaudinsReceptors, Lipoprotein

Identifiers

PMID24637461
PMCPMC3956714
OpenAlexW1986641387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.